Back to discover
Disease

Drug Hypersensitivity

Late-stage therapeutic developmentEmerging research
MeSHDrug Hypersensitivity
2
Publications
6
Clinical trials
12
Associated genes
2
Related proteins
2024
Latest publication
Current focus
Neurotrophin-3 biologyTherapeutic developmentInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2028.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Results expected Q3 20282026-05-26
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
1
Active
1
Late-stage
4
Completed
Late-stage studies

Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®

Phase 3 · Terminated · University Hospital, Rouen
Recruiting

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Phase 2 · Recruiting · Massachusetts General Hospital

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202024
Major themes5
  • Drug Hypersensitivity2
  • Dose-Response Relationship, Drug1
  • Hypersensitivity, Immediate1
  • Immune Checkpoint Inhibitors1
  • T-Lymphocytes1
Leading journals2
  • Allergy1
  • Toxicological sciences : an official journal of the Society of Toxicology1
Leading researchers8
  • Atanaskovic-Markovic M1
  • Barbaud A1
  • Betts C1
  • Bircher AJ1
  • Brockow K1
  • Caubet JC1
  • Celik G1
  • Cernadas J1
Affiliations (unnormalised)6
  • Allergy Clinic1
  • Ankara University School of Medicine1
  • Centre for Drug Safety Science1
  • Centro Hospitalar Universitário de S João1
  • Clinical Immunology and Allergy Unit1
  • Clinical Pharmacology and Safety Science1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

DPYS0.37ADISSP0.34CTTN0.33UBASH3B0.32MARCHF10.32FAR20.31NR4A20.31COL22A10.31DAAM10.31ZWINT0.30CWC220.29RAPGEF20.29

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Neurotrophin-3via NTF30.24Proliferation marker protein Ki-67via MKI670.24

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Immunologically mediated adverse reactions to medicinal substances used legally or illegally.

Identifiers
MeSHDrug Hypersensitivity
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.